Literature DB >> 28715159

Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men.

Seth C Kalichman1, Lisa Eaton1.   

Abstract

INTRODUCTION: Pre-exposure prophylaxis (PrEP) offers as much as 90% protection against HIV transmission. However, the effectiveness of PrEP depends on uptake and adherence to even intermittent dosing. Along with intoxication leading to unintentional non-adherence, believing that alcohol mixed with pharmaceuticals is harmful (i.e., interactive toxicity beliefs) may lead to poor uptake and intentional non-adherence.
METHODS: HIV-negative sexually active men who have sex with men (N = 272) at a large Gay Pride event in Atlanta, GA, completed anonymous surveys of demographic characteristics, sexual behaviour, alcohol use and PrEP-related alcohol interactive toxicity beliefs.
RESULTS: A total of 118 (43%) men surveyed had two or more male sex partners and condomless anal sex in the previous six months. Alcohol use was reported by over 90% of men and it was common for participants to believe that mixing alcohol and antiretrovirals is toxic; 75% endorsed at least one interactive toxicity belief. Among the 118 men who had engaged in condomless anal sex and had multiple sex partners, one in three stated that they were not interested in PrEP and men not interested in PrEP were significantly more likely to binge drink and hold interactive toxicity beliefs.
CONCLUSIONS: These results mirror studies that find interactive toxicity beliefs are a potent predictor of intentional antiretroviral non-adherence among people living with HIV and suggest interactive toxicity beliefs may impede PrEP uptake and adherence. Messages to increase PrEP awareness and adherence may also take steps to counter erroneous beliefs about mixing alcohol with antiretrovirals in the context of PrEP.

Entities:  

Keywords:  HIV prevention; men who have sex with men; pre-exposure prophylaxis; substance use

Mesh:

Substances:

Year:  2017        PMID: 28715159      PMCID: PMC5577742          DOI: 10.7448/IAS.20.1.21534

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


Introduction

Antiretroviral (ARV) medications are now at the forefront of HIV prevention, with pre-exposure prophylaxis (PrEP) offering the potential for protection against HIV transmission [1]. Most compelling are results of the iPrEx trial, which indicated that ARV exposure, specifically Truvada – the combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) – resulted in a 44% reduction in HIV incidence. Among the 100 men in iPrEx who became HIV infected, 36 received PrEP. However, ARV was detected in only 9% of infected men, indicating that PrEP resulted in over 90% protection. The difference between the 44% protection in overall findings versus 90% protection in the sub-analyses lies in adherence to a daily PrEP regimen [2-4]. Moreover, patterns of pill taking may strongly influence PrEP efficacy, with protection dropping to 34% with consecutive days of non-adherence [5]. As PrEP is scaled-up and targeted to populations at greatest risk for HIV infection, increased attention is needed to assure optimal levels of PrEP adherence [6]. Among the most robust threats to ARV adherence is substance use [7,8]. For example, individuals who use stimulants perceive greater concern that substance use can interfere with PrEP [9]. Furthermore, these concerns may impede uptake of PrEP among substance using individuals at risk for HIV, including men who have sex with men (MSM) [10]. All drugs of abuse may impede uptake and adherence to PrEP [11], with alcohol use posing the most common challenge [12,13]. Alcohol use impacts ARV adherence through multiple mechanisms, including disrupting memory, attention and sleep [14,15]. In parallel to therapeutic use of ARV, alcohol use is also associated with PrEP non-adherence [16]. While alcohol intoxication clearly leads to unintentional non-adherence, alcohol drinkers may also intentionally forego taking ARV because they believe that mixing alcohol with pharmaceuticals is harmful, referred to as interactive toxicity beliefs [17,18]. As many as one in four people living with HIV who drink alcohol stop taking ARV when drinking because they hold interactive toxicity beliefs [19,20]. These beliefs are common among people living with HIV, with more than half of HIV positive drinkers who take ARV stopping treatment when they are drinking [20]. Interactive toxicity beliefs are prevalent and directly associated with intentional non-adherence to the therapeutic use of ARV [18,21,22]. While these same beliefs may lead to hesitation to start PrEP as well as PrEP non-adherence, we are not aware of any research examining the potential for interactive toxicity beliefs to impede PrEP use. Because alcohol use is a robust predictor of sexual risks in populations vulnerable to HIV, drinking is likely prevalent among individuals who are candidates for PrEP [9]. Interactive toxicity beliefs directed towards PrEP may therefore risk PrEP refusal and intentional PrEP non-adherence. The current study focuses on PrEP interactive toxicity beliefs among MSM; 67% of US HIV infections occur among MSM and PrEP promotion in the US is most visibly targeted to this population [23]. We examined the degree to which MSM who may be appropriate for PrEP hold alcohol interactive toxicity beliefs and whether these beliefs may impede PrEP use.

Methods

Participants, setting and procedures

Participants were 394 men surveyed at the Atlanta Gay Pride Festival in October 2015. Surveys were collected using venue sampling procedures that have been reported in previous studies [10,24]. Participants were told that the survey was about health behaviours, contained personal questions about their behaviour, was anonymous, and would take 15 minutes to complete. Eighty per cent of men approached agreed to complete the survey. Participant names were not obtained on the surveys. Participants were offered $5 for completing the survey with an additional $5 donated to a local AIDS service organization. Participants provided a first name and last initial on receipts for payments unassociated with the surveys. We examined the surveys for completeness and checked for potential repeated surveys using the receipts. No repeat surveys were identified. The survey for this study is available as supplementary materials.

Ethical approval and consent

All participants were age 18 and older and provided verbal informed consent in compliance with conducting self-administered anonymous surveys.

Measures

Demographic characteristics

Participants were asked their age, years of education, income and race. Openness about sexual orientation was assessed with the item “How out are you about your sexual orientation?” with responses “not out about sexual orientation”, “sometimes out about sexual orientation” and “out about sexual orientation”. Participants also reported whether they had been tested for HIV and the result of their most recent HIV test.

Sexual behaviour

Participants reported the number of times they had engaged in anal intercourse as the insertive and receptive partner, with and without condoms in the past six months. Participants also recorded the number of sexual partners with whom they had engaged in each behaviour. Open response formats were used for the sexual behaviour measures to reduce response bias and to minimize measurement error [25]. Proportion of condom use during anal intercourse was calculated with the formula frequency of condom protected acts/total frequency of acts. Measures similar to these have been found reliable in self-reported sexual behaviour assessments [25,26].

Substance use

Three alcohol use items were adapted from the consumption scale of the Alcohol Use Disorders Identification Test [27,28], and were used to assess frequency and quantity of alcohol use with reference to current drinking. Specifically, we asked “how often do you have a drink containing alcohol?”, with responses “never”, “monthly or less”, “2–4 times a month”, “2–3 times a week” or “more than 4 times week”. Responses were recoded to represent none, monthly or at least weekly drinking. Quantity of alcohol consumption was assessed in terms of numbers of drinks in a typical drinking session, specifically “how may drinks containing alcohol do you have on a typical day when you are drinking?” (response categories shown in results). Finally, binge drinking was assessed using the item “How often do you have 6 or more drinks on one occasion?”, responses were “never”, “less than monthly”, “monthly”, “weekly” and “daily or almost daily” recoded to represent never, less than monthly and monthly or more often binge drinking. Participants were also asked whether they used cannabis, powder or crack cocaine, or other non-prescription drugs in the past six months coded dichotomously, Yes/No.

PrEP awareness

Participants were asked about their awareness and interest in PrEP. These measures specified the use of Truvada, the brand name for FTC/TDF, which is FDA approved for PrEP use. Items were adapted from previous research on PrEP awareness among MSM [29]. First, we provided participants with a standard definition of PrEP. Specifically, as part of the instructions the survey read “PrEP (pre-exposure prophylaxis) is when an HIV-negative person takes anti-HIV medications, also known as antiretrovirals and more specifically Truvada, BEFORE HAVING SEX to prevent HIV infection”. Participants responded Yes or No to each of the following: “Have you ever heard of PrEP?”, “Do you know anyone who is taking PrEP?”, “Are you currently taking PrEP?” and “Would you be interested in taking PrEP?”.

PrEP-related interactive toxicity beliefs

Truvada can itself have mild side effects, which can be amplified when mixed with alcohol. The Truvada pharmaceutical packaging states “Truvada may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Truvada with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it”. Thus, mixing Truvada with alcohol is not completely benign, but does not raise significant toxicity concerns, and there is no warning of health complications resulting from mixing Truvada with alcohol. We used five items to assess PrEP-related alcohol interactive toxicity beliefs that directly reflect beliefs regarding the potential health hazards from mixing alcohol with Truvada. Items were adapted from previous studies of therapeutic use of ARV and alcohol interactive toxicity beliefs [18,21]. Items are shown in the results and were responded to using a 4-point scale, from “Strongly disagree” to “Strongly agree”. Responses were dichotomized as agreement and disagreement for ease of interpretation. Interactive toxicity belief scores were also computed by taking the mean for the full range of responses, α = .89.

Data quality assurances and data analyses

All surveys were examined for inconsistencies and invalid responses that were treated as missing values (less than 5%), resulting in slightly different “n”s for analyses. For the purposes of this study, all main analyses were restricted to men who were sexually active with a male partner in the past six months and did not report having tested HIV positive. Within this sample, we used the following criteria to define men who were potentially appropriate for PrEP, or PrEP candidates; self-identified men who reported two or more male sex partners in the previous six months and at least one occasion of condomless anal intercourse. These criteria are narrower than the CDC PrEP guidelines, which include long-term serodiscordant partnerships and recent sexually transmitted infections [30]. We therefore focused on a subset of MSM who engage in behaviour well recognized as high risk for HIV infection and targeted by PrEP awareness campaigns [31]. We first compared men who were PrEP candidates (n = 118) to their non-candidate sexually active counterparts (n = 154). Second, we restricted the sample to only those participants who were defined as PrEP candidates and were currently drinking alcohol (n = 108) and compared men who were interested or currently taking PrEP (n = 73) to men who were not interested in PrEP (n = 35). This sub-analysis concentrated on participants who reported current alcohol use, the most relevant individuals in terms of questions of alcohol interactive toxicity beliefs and PrEP. Finally, we tested a multivariable model of interactive toxicity beliefs as predictors of interest in PrEP among MSM who drink and were candidates for PrEP. Analyses were performed using logistic regressions reporting odds ratios (OR) with 95% confidence intervals (95% CI). Data analyses were performed using SPSS, version 23.

Results

A total of 394 men completed surveys, of which 66 (17%) were HIV positive and 56 (14%) reported no same sex behaviour in the previous six months. The final sample therefore consisted of 272 sexually active MSM who had not tested HIV positive. A total of 118 (43%) men engaged in condomless anal sex and had multiple sex partners, defined here as PrEP candidates. The median number of condomless anal intercourse acts during that time period was four, ranging from 1 to 102. PrEP candidates had lower incomes, were younger, less likely to have health insurance, and less likely to have a healthcare provider, had significantly more male partners, were more likely to know someone taking PrEP and were more interested in taking PrEP (see Table 1).
Table 1.

Characteristics of sexually active MSM who are not and who are PrEP candidates

 Not a PrEP candidate(N = 154)
PrEP candidate(N = 118)
 
CharacteristicN%N%OR95% CI
Race     
Caucasian88576455Reference
African American422735301.330.47–3.79
Hispanic/Latino13812101.520.51–4.54
Other race117651.690.48–6.00
Income <$15,00025163227  
$16,000–$30,00029192925  
$31,000–$45,00030203421  
$46,000–$60,00027181311  
>$60,000422719160.80*0.69–0.92
Employed1238094801.010.55–1.84
Has health insurance1278386730.55*0.30–0.98
Has healthcare provider1328790760.49*0.26–0.92
Not openly Gay8511Reference
Sometimes openly Gay402729250.140.02–1.19
Always openly Gay1026887740.850.49–1.48
Heard of PrEP986487731.60+0.94–2.71
Knows someone taking PrEP533463532.18**1.33–3.56
Currently taking PrEP10714121.950.83–4.57
Interested in taking PrEP614077662.90**1.76–4.79
 MSDMSD  
Age (years)37.112.830.612.10.95**0.93–0.97
Education (years)14.42.214.52.11.020.92–1.14
Number male partners2.64.36.78.11.19**1.11–1.29
Condomless anal sex10.229.89.114.60.990.98–1.01
Percentage of condom use-anal intercourse46.545.138.130.20.560.29–1.09

Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis; +p < .10, *p < .05, **p < .01.

Characteristics of sexually active MSM who are not and who are PrEP candidates Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis; +p < .10, *p < .05, **p < .01.

Substance use among PrEP candidates and non-candidates

The majority of men (91%) reported current alcohol use, with 47% drinking lightly (1–2 drinks per session). However, nearly two out of three men reported binge drinking. There was a trend towards PrEP candidates being more likely to binge drink than those who were not PrEP candidates. PrEP candidates were also more likely to report recent cannabis and other drug use (see Table 2).
Table 2.

Substance use and PrEP-related interactive toxicity beliefs among sexually active MSM who are not and who are PrEP candidates

 Not a PrEP candidate(N = 154)
PrEP candidate(N = 118)
  
CharacteristicN%N%OR95% CI
Frequency of alcohol use      
None161198Reference 
Monthly775061520.720.29–1.76
At least weekly603947401.010.61–1.68
Quantity of alcohol use      
Does not drink20131210Reference 
1–2 drinks795249421.200.19–7.57
3–4 drinks332231271.240.22–7.02
5–6 drinks151016131.880.32–10.99
7+ drinks63982.130.34–13.40
Binge drinking      
Does not binge drink69453429Reference 
Binge drinks less than monthly483152440.57+0.30–1.06
Binge drinks monthly or more372432271.250.67–2.31
Drug use in past six months      
Cannabis use493255571.89**1.13–3.07
Cocaine use13911101.110.48–2.58
Other non-prescription drug use4315135.46**1.76–16.92
PrEP interactive toxicity beliefs     
Alcohol and PrEP should never be mixed1006568570.720.43–1.19
A person should stop takingPrEP if they are drinking714744370.710.43–1.16
Alcohol interferes with PrEPso it will not work right785351450.720.44–1.19
Mixing alcohol with HIV medications like PrEP is dangerous875960530.780.47–1.28
Drinking alcohol while taking PrEP is toxic to the body’s system845657500.770.47–1.26

Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis; +p < .07,  **p < .01.

Substance use and PrEP-related interactive toxicity beliefs among sexually active MSM who are not and who are PrEP candidates Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis; +p < .07,  **p < .01.

Interactive toxicity beliefs among PrEP candidates and non-candidates

More than 75% of participants endorsed at least one PrEP-related alcohol interactive toxicity belief, with 61% (168/272) of the sample stating that alcohol and PrEP should never be mixed and 42% (115/272) stating that a person should stop taking PrEP if they are drinking (see Table 2). More than half of the sample endorsed three or more PrEP-related alcohol interactive toxicity beliefs, with an average of 2.6 (SD = 0.85) interactive toxicity beliefs endorsed. The prevalence of alcohol interactive toxicity beliefs was therefore high, and there were no significant differences between PrEP candidates and non-candidates in their rates of endorsing interactive toxicity beliefs.

Interactive toxicity beliefs among PrEP candidates who drink and are not or are interested in taking PrEP

Among the 118 men who were candidates for PrEP, ten did not report current alcohol use and were removed from these analyses. For the 108 PrEP candidates who currently used alcohol, 73 (66%) were interested in using PrEP (see Table 3). With respect to binge drinking, men who were interested in PrEP were more likely to binge drink on monthly or less frequently basis but were less likely to binge drink monthly or more often. Thus, men interested in PrEP were more likely to be infrequent binge drinkers, but not frequent binge drinkers. Nearly all individuals interested in PrEP (91%) had previously heard about PrEP compared to 37% of those not interested. In addition, 67% of interested persons knew someone taking PrEP compared to 23% of the non-interested.
Table 3.

Substance use and PrEP-related interactive toxicity beliefs among sexually active MSM who are candidates for PrEP and drink alcohol who are not and who are interested in PrEP

 Not interested in PrEP(N = 35)
Interested in PrEP(N = 73)
Unadjusted
 
CharacteristicN%N%OR95% CI
Current alcohol use      
Frequency of alcohol use      
Monthly16464461Reference 
At least weekly195428390.830.53–1.28
Quantity of alcohol use      
1–2 drinks15433750Reference 
3–4 drinks123419261.200.26–5.43
5–6 drinks51411150.790.16–3.77
7+ drinks39691.100.19–6.28
Binge drinking      
Does not binge drink7201622Reference 
Binge drinks less than monthly113141572.590.83–7.99
Binge drinks monthly or more174915214.22**1.61–11.05
Cannabis154338531.490.66–3.36
Cocaine4117100.830.23–3.06
Other non-prescription drugs51410140.960.30–3.08
Heard of PrEP 1337669118.61**6.31–54.87
Knows someone taking PrEP 82348676.75**2.66–17.08
Currently taking PrEP 0 1217n/a 
PrEP interactive toxicity beliefs     
Alcohol and PrEP shouldnever be mixed216243610.990.42–2.29
A person should stop takingPrEP if he/she is drinking195821300.32**0.14–0.76
Alcohol interferes with PrEPso it will not work right216426370.34**0.14–0.82
Mixing alcohol with HIVmedications like PrEP is dangerous226834490.480.21–1.15
Drinking alcohol whiletaking PrEP is toxicto the body’s system226729420.36**0.15–0.80
Number beliefs endorsed      
07212333  
113811  
2514913  
326811  
4–5195622310.76**0.58–0.97
Mean (SD) beliefs score2.860.772.400.950.55**0.33–0.89

Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis;  **p < .01.

Substance use and PrEP-related interactive toxicity beliefs among sexually active MSM who are candidates for PrEP and drink alcohol who are not and who are interested in PrEP Note: OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis;  **p < .01. Overall, more than three in four participants who were alcohol-using PrEP candidates endorsed at least one interactive toxicity belief. PrEP candidates who were not interested in using PrEP endorsed more PrEP-related alcohol interactive toxicity beliefs. Men who were not interested in PrEP were more likely to believe that a person should stop taking PrEP when drinking, and that mixing PrEP with alcohol renders PrEP less effective and toxic. However, more than two-thirds of men interested in PrEP still endorsed at least one interactive toxicity belief, with 30% stating that PrEP should be stopped when drinking (see Table 3). The multivariable logistic regression model predicting PrEP interest from interactive toxicity beliefs among alcohol using PrEP candidates, controlling for age, race, years of education, employment status, income, number of male sex partners, knowing someone taking PrEP, frequency of alcohol use and binge drinking was significant, X2 (10) = 40.20, p < .01. Men interested in PrEP were significantly more likely to know someone taking PrEP, OR = 17.09, p < .01, 95% CI = 3.70–78.90, less likely to drink binge, OR = 0.34, p < .01, 95% CI = 0.16–0.73, and were less likely to endorse alcohol interactive toxicity beliefs, OR = 0.43, p < .05, 95% CI = 0.19–0.93.

Interactive toxicity beliefs among men taking PrEP

A total of 24 participants, 9% of the sample and 20% of men who we defined as PrEP candidates, indicated that they were currently taking PrEP. Alcohol use was common among PrEP users, with 21 (88%) reporting current alcohol use and 13 (54%) binge drinking. PrEP-related alcohol interactive toxicity beliefs among men taking PrEP mirrored those observed in the larger sample with 50% of men taking PrEP endorsing at least one interactive toxicity belief and one-in-four endorsing multiple beliefs. One third of men taking PrEP indicated that alcohol and PrEP should never be mixed.

Discussion

This is the first study that we are aware of that examines interactive alcohol toxicity beliefs in a population targeted for HIV PrEP. Consistent with a growing body of research that shows beliefs that mixing alcohol with ARV leads to intentional non-adherence among some alcohol and drug users living with HIV [20,21,32,33], we found that interactive toxicity beliefs may impede PrEP uptake and adherence. A majority of men surveyed held alcohol-PrEP interactive toxicity beliefs, with three out of four endorsing at least one belief that mixing alcohol and ARV is dangerous. Among men who were PrEP candidates, interactive toxicity beliefs were more prevalent among men who were not interested in PrEP than those men who were interested. In a multivariable model knowing someone who has taken PrEP, binge drinking and interactive toxicity beliefs differentiated PrEP candidates who were and were not interested in PrEP. Thus, it is possible that binge drinking and alcohol interactive toxicity beliefs contribute to diminished interest in PrEP, while knowing someone who uses PrEP has the opposite effect. In addition, two out of three PrEP candidates who are interested in PrEP endorsed interactive toxicity beliefs that are known to predict intentional non-adherence among people living with HIV [21]. These results suggest that alcohol interactive toxicity beliefs are a potential barrier to PrEP uptake and adherence, particularly among men who drink in greater quantities. The current findings should be considered in light of the study methodological limitations. This study was a cross-sectional survey with a convenience sample of men attending a large gay pride event in a city in the southeastern USA. It is likely that our sample over-represents men who are open about their sexual orientation and connected to the lesbian, gay, bisexual and transgender  (LGBT) community. Our sample size was also relatively small in size with some analyses based on sparse cells and large confidence intervals. In addition, we did not use current CDC guidelines to define PrEP candidates. Rather, we used a narrower definition based on multiple partners and condomless anal sex. Our survey also relied on self-reports of socially sensitive behaviours. Although using an anonymous procedure minimized the potential influences of social desirability, studies such as ours can still yield biased data, and these biases must be considered when interpreting our findings. Another potential constraint on our results is the risk for individuals to complete multiple surveys for the incentive payment. Although we had a procedure for protecting against repeat surveys, we cannot be certain this did not occur. Our study also focused on alcohol use and alcohol-related beliefs. We recognize the potential for interactive toxicity beliefs in relation to other drugs and PrEP use. The association between alcohol and other drugs may influence interactive toxicity beliefs and should be examined in future research. Acknowledging these limitations, we believe that our findings have important implications for implementing and scaling-up PrEP. Scaling-up PrEP has the potential to alter the course of HIV epidemics, but faces multiple challenges including increasing PrEP awareness and increasing access to health services for the uninsured [10,29]. Interactive toxicity beliefs are prevalent and may stem from an over-generalization of the potential mild interactions of Truvada and alcohol as well as recommendations to not drink when taking any medications that adversely interact with alcohol [34]. Medication adherence is hampered by concerns about side effects, dependence, and adverse outcomes [35]. In addition, PrEP carries added concerns about stigmas that are assumed with sexual risks [36]. Along with these concerns, providers should assess and directly address alcohol interactive toxicity beliefs among PrEP candidates. Failure to discuss the safety of alcohol use while taking PrEP will leave erroneous beliefs unchecked and risk PrEP refusal and intentional non-adherence.

Conclusions

The same interactive toxicity beliefs that predict intentional ARV non-adherence among people living with HIV were found to potentially impede PrEP uptake and adherence. Messages aimed to increase PrEP awareness and adherence may take proactive steps to counter erroneous beliefs about mixing alcohol with ARV in the context of PrEP.
  34 in total

Review 1.  Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports.

Authors:  Kerstin E E Schroder; Michael P Carey; Peter A Vanable
Journal:  Ann Behav Med       Date:  2003-10

Review 2.  The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature.

Authors:  Shannon M Sweeney; Peter A Vanable
Journal:  AIDS Behav       Date:  2016-01

3.  Beliefs about treatments for HIV/AIDS and sexual risk behaviors among men who have sex with men, 1997-2006.

Authors:  Seth C Kalichman; Lisa Eaton; Denise White; Charsey Cherry; Howard Pope; Demetria Cain; Moira O Kalichman
Journal:  J Behav Med       Date:  2007-08-10

4.  Alcohol-antiretroviral therapy interactive toxicity beliefs and daily medication adherence and alcohol use among people living with HIV.

Authors:  Jennifer A Pellowski; Seth C Kalichman; Moira O Kalichman; Chauncey Cherry
Journal:  AIDS Care       Date:  2016-03-10

Review 5.  Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.

Authors:  Santosh Kumar; P S S Rao; Ravindra Earla; Anil Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-12-24       Impact factor: 4.481

Review 6.  Methodological problems in AIDS behavioral research: influences on measurement error and participation bias in studies of sexual behavior.

Authors:  J A Catania; D R Gibson; D D Chitwood; T J Coates
Journal:  Psychol Bull       Date:  1990-11       Impact factor: 17.737

7.  Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART.

Authors:  Robert Horne; Deanna Buick; Martin Fisher; Heather Leake; Vanessa Cooper; John Weinman
Journal:  Int J STD AIDS       Date:  2004-01       Impact factor: 1.359

8.  High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.

Authors:  Elisabeth Maria Van der Elst; Judie Mbogua; Don Operario; Gaudensia Mutua; Caroline Kuo; Peter Mugo; Jennifer Kanungi; Sagri Singh; Jessica Haberer; Frances Priddy; Eduard Joachim Sanders
Journal:  AIDS Behav       Date:  2013-07

9.  Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS.

Authors:  Bach Xuan Tran; Long Thanh Nguyen; Cuong Duy Do; Quyen Le Nguyen; Rachel Marie Maher
Journal:  BMC Public Health       Date:  2014-01-10       Impact factor: 3.295

10.  Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).

Authors:  Patricia A Defechereux; Megha Mehrotra; Albert Y Liu; Vanessa M McMahan; David V Glidden; Kenneth H Mayer; Lorena Vargas; K Rivet Amico; Piotr Chodacki; Telmo Fernandez; Vivian I Avelino-Silva; David Burns; Robert M Grant
Journal:  AIDS Behav       Date:  2016-07
View more
  8 in total

1.  Substance Use and Healthcare Utilization Across the Pre-Exposure Prophylaxis (PrEP) Care Cascade among Black and Latino Men Who Have Sex with Men.

Authors:  Ryan J Watson; Ethan Morgan; Charlene Collibee; Jolaade Kalinowski; Casey Cunningham; E Jennifer Edelman; Philip Chan; Lisa A Eaton
Journal:  Subst Use Misuse       Date:  2022-08-08       Impact factor: 2.362

2.  Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A Methodological Review.

Authors:  Rogério M Pinto; Ashley Lacombe-Duncan; Emma Sophia Kay; Kathryn R Berringer
Journal:  AIDS Behav       Date:  2019-10

3.  Knowledge of PEP and PrEP among people living with HIV/aids in Brazil.

Authors:  Laelson Rochelle Milanês Sousa; Henrique Ciabotti Elias; Nilo Martinez Fernandes; Elucir Gir; Renata Karina Reis
Journal:  BMC Public Health       Date:  2021-01-07       Impact factor: 3.295

4.  Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men.

Authors:  Paul A Shuper; Narges Joharchi; Isaac I Bogoch; Mona Loutfy; Frederic Crouzat; Philippe El-Helou; David C Knox; Kevin Woodward; Jürgen Rehm
Journal:  BMC Public Health       Date:  2020-11-25       Impact factor: 3.295

5.  Game Plan-a Brief Web-Based Intervention to Improve Uptake and Use of HIV Pre-exposure Prophylaxis (PrEP) and Reduce Alcohol Use Among Gay and Bisexual Men: Content Analysis.

Authors:  Philip A Chan; Tyler B Wray; John P Guigayoma; Christopher W Kahler
Journal:  JMIR Form Res       Date:  2022-01-05

6.  Game Plan, a Web-Based Intervention to Improve Adherence and Persistence to HIV Pre-exposure Prophylaxis and Reduce Heavy Drinking in Gay, Bisexual, and Other Men Who Have Sex With Men: Usability and User Experience Testing.

Authors:  Tyler B Wray; Philip A Chan; Christopher W Kahler
Journal:  JMIR Form Res       Date:  2021-11-16

7.  The Role of Alcohol-Related Behavioral Risk in the Design of HIV Prevention Interventions in the Era of Antiretrovirals: Alcohol Challenge Studies and Research Agenda.

Authors:  William H George; Jessica A Blayney; Cynthia A Stappenbeck; Kelly Cue Davis
Journal:  AIDS Behav       Date:  2021-07-09

Review 8.  Addressing Unhealthy Alcohol Use and the HIV Pre-exposure Prophylaxis Care Continuum in Primary Care: A Scoping Review.

Authors:  Benjamin J Oldfield; E Jennifer Edelman
Journal:  AIDS Behav       Date:  2020-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.